Unicycive Therapeutics Stock News

Use these tips for identifying promising penny stocks The post How to Identify Promising Penny Stocks: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Use these tips for future proofing your penny stocks strategy The post How to Future Proof Your Penny Stocks Investing Strategy  appeared first on Penny Stocks to Buy, Picks, News and Information | P

What you need to know about day trading penny stocks The post Penny Stocks Investing: The Pros and Cons of Day Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.

Use these tips for trading penny stocks during market uncertainty The post Penny Stocks Trading: Tips for Market Uncertainty  appeared first on Penny Stocks to Buy, Picks, News and Information | Penn

Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to

Presentation to Highlight Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction Presentation to Highlight Late-Stage Program in Hyperphosphate

In the last trading session, 1.06 million shares of the Unicycive Therapeutics Inc. (NASDAQ:UNCY) were traded. Most recently the company’s share price was $1.36, and it changed around -$0.02 or -1.45% from the last close, which brings the market valuation of the company to $19.64M. UNCY currently trades at a discount to its 52-week high … Unicycive Therapeutics Inc. (NASDAQ: UNCY): A Stock Worth Thinking About Today Read More »

Unicycive Therapeutics Inc (UNCY) shares closed this week 21.0% lower than it did at the end of last week. The stock is currently down 12.6% year-to-date, down 69.2% over the past 12 months, and down 69.2% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $2.29 and as low as $1.68 this week.Shares closed 78.9% below its 52-week high and 9.5% above its 52-week low.Trading volume this week was 53.8% lower than the 10-day average and 34.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 775.1% The company's stock price performance over the past 12 months lags the peer average by 315.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Unicycive Therapeutics Inc (NASDAQ: UNCY ) updated the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate). Renazorb is a second-generation lanthanum-based phosphate-binding agent utilizing proprietary nanoparticle technology for hyperphosphatemia in patients with chronic kidney disease (CKD). In a recent Type C interaction with the FDA, Unicycive sought the FDA''s feedback on the sufficiency of the Renazorb Full story available on Benzinga.com

Unicycive Therapeutics Inc (NASDAQ: UNCY) updated the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate).  Renazorb is a second-generation lanthanum-based phosphate-

LOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today provided an update on the development and regulatory filing pathway for Renazorb (lanthanum

Unicycive Therapeutics (NASDAQ:UNCY) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a report released on Thursday, Zacks.com reports. According to Zacks, Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The companys lead drug consist Renazorb, is a []

LOS ALTOS, Calif., Sept. 15, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today anno